DK3651768T3 - Heterocykliske inhibitorer af atr-kinase - Google Patents

Heterocykliske inhibitorer af atr-kinase Download PDF

Info

Publication number
DK3651768T3
DK3651768T3 DK18831104.7T DK18831104T DK3651768T3 DK 3651768 T3 DK3651768 T3 DK 3651768T3 DK 18831104 T DK18831104 T DK 18831104T DK 3651768 T3 DK3651768 T3 DK 3651768T3
Authority
DK
Denmark
Prior art keywords
atr kinase
heterocyclic inhibitors
heterocyclic
inhibitors
atr
Prior art date
Application number
DK18831104.7T
Other languages
English (en)
Inventor
Francesco Maria Emilia Di
Philip Jones
Christopher Lawrence Carroll
Jason Bryant Cross
Suyambu Kesava Vijayan Ramaswamy
Michael Garrett Johnson
Sarah Lively
David Lapointe
Original Assignee
Univ Texas
Chempartner Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Chempartner Corp filed Critical Univ Texas
Application granted granted Critical
Publication of DK3651768T3 publication Critical patent/DK3651768T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18831104.7T 2017-07-13 2018-07-13 Heterocykliske inhibitorer af atr-kinase DK3651768T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762531951P 2017-07-13 2017-07-13
PCT/US2018/042128 WO2019014618A1 (en) 2017-07-13 2018-07-13 HETEROCYCLIC INHIBITORS OF KINASE ATR

Publications (1)

Publication Number Publication Date
DK3651768T3 true DK3651768T3 (da) 2024-03-18

Family

ID=64998660

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18831104.7T DK3651768T3 (da) 2017-07-13 2018-07-13 Heterocykliske inhibitorer af atr-kinase

Country Status (18)

Country Link
US (3) US10392376B2 (da)
EP (1) EP3651768B1 (da)
JP (1) JP7159307B2 (da)
KR (1) KR102676822B1 (da)
CN (2) CN117466884A (da)
AU (1) AU2018301696B8 (da)
CA (1) CA3069693A1 (da)
DK (1) DK3651768T3 (da)
ES (1) ES2974334T3 (da)
FI (1) FI3651768T3 (da)
IL (1) IL271930B (da)
LT (1) LT3651768T (da)
MX (1) MX2020000386A (da)
PH (1) PH12020500072A1 (da)
PT (1) PT3651768T (da)
RS (1) RS65466B1 (da)
SI (1) SI3651768T1 (da)
WO (1) WO2019014618A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630116B1 (en) 2017-05-26 2024-05-01 The Board Of Regents Of The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
CN117466884A (zh) * 2017-07-13 2024-01-30 德州大学系统董事会 用作atr激酶抑制剂的杂环化合物或其盐、包含其的药物组合物及用途
CN111886224A (zh) 2017-08-17 2020-11-03 德州大学系统董事会 Atr激酶的杂环抑制剂
JP7235338B2 (ja) * 2017-09-08 2023-03-08 ニューウェーブ・ファーマスーティカル・インコーポレイテッド Atr阻害剤としての置換ピロロピリジン
US10894052B2 (en) 2018-03-16 2021-01-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
WO2020063751A1 (en) * 2018-09-27 2020-04-02 Fochon Pharmaceuticals, Ltd. Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors
CN112047938B (zh) * 2019-06-06 2022-11-22 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
WO2021238999A1 (zh) * 2020-05-29 2021-12-02 深圳市瓴方生物医药科技有限公司 氟代吡咯并吡啶类化合物及其应用
CN116848113A (zh) * 2021-02-10 2023-10-03 南京再明医药有限公司 作为hpk1抑制剂的双环类化合物及其应用
CN117500789A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081338A1 (en) * 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
KR20080083188A (ko) * 2006-01-11 2008-09-16 아스트라제네카 아베 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
EP2057140B1 (en) 2006-08-24 2012-08-08 AstraZeneca AB Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
WO2008032072A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
MX2009010881A (es) 2007-04-12 2009-12-14 Hoffmann La Roche Compuestos farmaceuticos.
WO2008144500A2 (en) 2007-05-17 2008-11-27 Anadys Pharmaceuticals, Inc. 1-methyl-benzo[1,2,4]thiadiazine, 1-oxide derivatives
CA2692725A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Compound - 946
US8138183B2 (en) 2007-07-09 2012-03-20 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
KR20100031639A (ko) 2007-07-09 2010-03-23 아스트라제네카 아베 증식성 질환의 치료용 삼중 치환된 피리미딘 유도체
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Msd株式会社 アルキルアミノピリジン誘導体
AU2009266806A1 (en) 2008-07-03 2010-01-07 Exelixis Inc. CDK modulators
TW201028410A (en) 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
WO2010120996A1 (en) 2009-04-17 2010-10-21 Wyeth Llc 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011106276A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
EP2542536B1 (en) 2010-03-04 2015-01-21 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
CA2892608C (en) 2012-12-07 2021-10-19 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
SG10201804791UA (en) 2013-12-06 2018-07-30 Vertex Pharma 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
PT3152212T (pt) 2014-06-05 2020-03-13 Vertex Pharma Derivados radiomarcados de um composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor de atr quinase, preparação do dito composto e diferentes formas sólidas do mesmo
TWI700283B (zh) * 2014-08-04 2020-08-01 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
CA2963973C (en) 2014-10-13 2023-01-10 Atrin Pharmaceuticals LLC Macrocylic compounds as ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors
CA3026149A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
EP3630116B1 (en) 2017-05-26 2024-05-01 The Board Of Regents Of The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
CN117466884A (zh) * 2017-07-13 2024-01-30 德州大学系统董事会 用作atr激酶抑制剂的杂环化合物或其盐、包含其的药物组合物及用途
CN111886224A (zh) 2017-08-17 2020-11-03 德州大学系统董事会 Atr激酶的杂环抑制剂
US10894052B2 (en) 2018-03-16 2021-01-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase

Also Published As

Publication number Publication date
US10392376B2 (en) 2019-08-27
WO2019014618A1 (en) 2019-01-17
IL271930B (en) 2022-07-01
CN111867590B (zh) 2023-11-17
AU2018301696A1 (en) 2020-02-27
EP3651768B1 (en) 2023-12-20
US20190016713A1 (en) 2019-01-17
KR102676822B1 (ko) 2024-06-19
JP7159307B2 (ja) 2022-10-24
JP2020527174A (ja) 2020-09-03
LT3651768T (lt) 2024-04-25
EP3651768A1 (en) 2020-05-20
SI3651768T1 (sl) 2024-05-31
EP3651768A4 (en) 2021-04-07
US10800769B2 (en) 2020-10-13
RS65466B1 (sr) 2024-05-31
MX2020000386A (es) 2020-08-06
KR20200028441A (ko) 2020-03-16
FI3651768T3 (fi) 2024-03-14
CN117466884A (zh) 2024-01-30
CA3069693A1 (en) 2019-01-17
CN111867590A (zh) 2020-10-30
US20210047311A1 (en) 2021-02-18
IL271930A (en) 2020-02-27
US20200102296A1 (en) 2020-04-02
ES2974334T3 (es) 2024-06-26
AU2018301696A8 (en) 2023-03-23
AU2018301696B8 (en) 2023-03-23
US11434233B2 (en) 2022-09-06
AU2018301696B2 (en) 2022-10-27
PT3651768T (pt) 2024-03-20
PH12020500072A1 (en) 2020-11-09

Similar Documents

Publication Publication Date Title
DK3651768T3 (da) Heterocykliske inhibitorer af atr-kinase
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3710439T3 (da) Kras g12c-hæmmere
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3371171T3 (da) Inhibitorer af RET
DK3303334T3 (da) Tyrosinkinasehæmmere
DK3423451T3 (da) Inhibitorer af wdr5-protein-proteinbinding
DK3377059T3 (da) Hæmmere af cxcr2
DK3442977T3 (da) Inhibitorer af activinreceptorlignende kinase
DK3298002T3 (da) Heterocykliske amider som kinasehæmmere
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
MA42242A (fr) Inhibiteurs de la tyrosine kinase
DK3704120T3 (da) Heterocykliske forbindelser som prmt5-inhibitorer
DK3442972T3 (da) Bromdomænehæmmere
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
IL279949A (en) Heterocyclic MCT4 inhibitors
EP3668839A4 (en) HETEROCYCLIC INHIBITORS OF THE ATR KINASE
DK3613737T3 (da) Hidtil ukendt inhibitor af cyclin-afhængig kinase CDK9
DK3457851T3 (da) Derivater af sobetirom
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3215493T3 (da) Syntese af copanlisib og dihydrochloridsalt deraf
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3302550T3 (da) Kombination af et anti-cd19 antistof og en brutons tyrosine kinase-inhibitor og anvendelse deraf
DK3630744T3 (da) Pyrazol-magl-inhibitorer